Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

Rather than acknowledge the harm caused by such facilities, activists are attempting to slander the victims You can save this article by registering for free here. Or sign-in if you have an account.

In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, allowing for one- to two-minute administration across 38 solid tumor ...

A used needle is seen on the ground on Friday, March 22, 2024, in Baker Park in Grants Pass, Ore. The two candidates vying to represent District 7 on Boston City Council have different opinions about ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...

The Boston City Council struck down a resolution opposing safe injection sites, with proponents rejecting notions that legalizing such centers would incentivize addicts to shoot up and saying that ...

Patients can now receive treatment in as little as one to two minutes, compared to a 30-minute IV infusion New option offers greater convenience and flexibility in treatment settings, from hospitals ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...